ANNX Projected Dividend Yield
Annexon Inc ( NASDAQ : ANNX )Annexon is a clinical-stage biopharmaceutical company developing a class of complement medicines designed to stop the classical complement pathway at its start, C1q, in order to bring therapies to patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. Co. is developing a pipeline of product candidates designed to block the activity of C1q and the entire classical complement pathway for a range of complement-mediated diseases. Co.'s pipeline includes three clinical-stage assets across three therapeutic franchises: autoimmune, neurodegenration and ophtamology. Co. its developing its primary candidate, ANX005. 20 YEAR PERFORMANCE RESULTS |
ANNX Dividend History Detail ANNX Dividend News ANNX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |